(Q37472650)

20 August 2017

1 reference

title

Treatment of Alzheimer's disease in the long-term-care setting (English)

1 reference

20 August 2017

0 references

David A Smith

1

1 reference

20 August 2017

language of work or name

1 reference

1 May 2009

1 reference

American Journal of Health-System Pharmacy

20 August 2017

published in

1 reference

20 August 2017

volume

66

1 reference

20 August 2017

issue

10

1 reference

20 August 2017

page(s)

899-907

1 reference

Alzheimer Disease in the US Population

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Dementia in subjects aged 75 years or over within the PAQUID cohort: prevalence and burden by severity.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Missing the diagnosis: senile dementia in patients admitted to nursing homes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

The recognition of dementia in "non-EMI" nursing home residents in South East England

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Improved evaluation and management of cognitive impairment: results of a comprehensive intervention in long-term care

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

A new rating scale for Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

3-year study of donepezil therapy in Alzheimer's disease: effects of early and continuous therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

An assessment of the diagnosis and management of dementia in nursing homes.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Donepezil use in US nursing homes.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Memantine in moderate-to-severe Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Donepezil preserves cognition and global function in patients with severe Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070622

31 March 2020

Identifiers

DOI

10.2146/AJHP070622

1 reference

20 August 2017

1 reference